Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 5Brain Neoplasms 4Esophageal Neoplasms 2EGF-R Positive Non-Small Cell Lung Cancer 2Adenocarcinoma of Lung 2Squamous Cell Carcinoma of Lung 1Plasma EGFR Mutation-positive Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Drug-Related Side Effects and Adverse Reactions 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 51Gemcitabine 26toripalimab 20Radiotherapy, Intensity-Modulated 19Fluorouracil 16Capecitabine 16camrelizumab 15Docetaxel 14nimotuzumab 12Radiotherapy 10Drug Therapy 10apatinib 9Nivolumab 9sintilimab 8endostar protein 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Immune Checkpoint Inhibitors 7tislelizumab 6spartalizumab 6Chemoradiotherapy 6Cetuximab 6Bevacizumab 6pembrolizumab 5nedaplatin 5S 1 (combination) 5Radiation 5Paclitaxel 5Endostatins 5anlotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Nasopharyngeal Carcinoma × icotinib × Clear all
NCT02328261 2014-12-31

A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
66 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡